Dose-dependent neuroprotective effect of enoxaparin on cold-induced traumatic brain injury
Neural Regeneration Research, 2017 Recent evidence exists that enoxaparin can reduce brain injury because of its anticoagulant activity. To investigate the potential therapeutic effect of enoxaparin on cold-induced traumatic brain injury, at 20 minutes after modeling, male BALB/c mouse ...
Ilknur Keskin +5 more
doaj +1 more source
Micro-computed tomography for the quantification of blocked fibers in hemodialyzers [PDF]
, 2018 A novel technique based on micro-CT scanning is developed to quantify coagulation in fibers of hemodialyzers. This objectivation is needed to allow accurate assessment of thrombogenicity of dialyzers used during hemodialysis, for example when comparing ...
Boone, Matthieu +5 more
core +2 more sources
Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in Low Body Weight Patients
Clinical Medicine Insights: Blood Disorders, 2019 Background: The appropriate dose of enoxaparin for venous thromboembolism (VTE) prophylaxis in low body weight patients is unknown. Objective: The aim of this study is to evaluate the impact of enoxaparin dosing on major and minor bleeding events in low ...
Daniel Dybdahl +4 more
doaj +1 more source
Plasmatology, 2023 Background Although reduced doses of enoxaparin have been studied in low body weight patients, no study has directly compared enoxaparin to unfractionated heparin for venous thromboembolism (VTE) prophylaxis in this population. Objective To determine the
David Michael Kaylor PharmD +4 more
doaj +1 more source
Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. [PDF]
, 2018 It is common knowledge that cancer patients are more prone to develop venous thromboembolic complications (VTE). It is therefore not surprising that patients with hepatocellular carcinoma (HCC) present with a significant risk of VTE, with the portal vein
Burra, P +5 more
core +1 more source
Enoxaparin-induced reactive thrombocytosis: a case report
Thrombosis Journal, 2021 Background Enoxaparin is an anticoagulant that falls in the class of medications called low molecular weight heparins (LMWHs), and is used to prevent or treat patients with deep vein thrombosis (DVT) and pulmonary embolism.
Tao Xiang, Ming Cheng
doaj +1 more source
Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD [PDF]
, 2018 Background Enoxaparin may be used to prevent central venous catheter-related thrombosis in patients with CHD. We aimed to determine whether current enoxaparin dosing regimens effectively achieve anti-factor Xa concentrations within prophylactic goal ...
Israel, Emily N. +2 more
core +1 more source
Efficacy, Safety, and Timing of Anticoagulant Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients With Acute Spinal Cord Injury: A Systematic Review [PDF]
, 2017 Study Design: Systematic review. Objectives: The objective of this study was to answer 5 key questions: What is the comparative effectiveness and safety of (1a) anticoagulant thromboprophylaxis compared to no prophylaxis, placebo, or another ...
Arnold, Paul M. +10 more
core +2 more sources
Pharmacy Practice, 2019 Background: There is limited information describing pharmacist participation in prophylactic enoxaparin monitoring in the surgical intensive care unit (SICU).
Scrimenti A +6 more
doaj +1 more source
Electronic risk assessment for venous thromboembolism: investigating physicians' rationale for bypassing clinical decision support recommendations. [PDF]
, 2014 Objective: The underutilisation of venous thromboembolism (VTE) prophylaxis is still a problem in the UK despite the emergence of national guidelines and incentives to increase the number of patients undergoing VTE risk assessments.
Brooks, Hannah +4 more
core +3 more sources